CoviDx™ SARS CoV-2 Rapid Antigen Test

Spectrum Medical Diagnostics is pleased to launch the latest rapid COVID-19 antigen screening device designed to detect the new known variants!

This product is made in North America and offers superior clinical accuracy & sensitivity.

Enhance your COVID-19 screening protocol with this new, highly sensitive test to guarantee the safety of your workplace and employees.

Key Product Features

  • Specimen type: Nasal or Nasopharyngeal.
  • Results: 15-20 minutes.
  • Pre-filled buffer vials.
  • Made in North America.
  • Simple test procedure.
  • Simple results interpretation.

Interested in learning more about the product?

Contact us here with any questions you may have!

Clinical Information

  • Diagnoses at the point of care.
    • Performance demonstrated 100% PPA and 95% NPA in patientswith Ct values < 352.
    • Clinical performance compared against high sensitivity PCR gold standard3.
    • High specificity despite times of low prevalence during enrollment.
  • Pre-filled extraction vials standardize workflow and enable greater test distribution via multiple independent workstations.

Additional Information

  1. Testing should follow provincial or territorial guidance and be administered regularly to employees in accordance with the interim guidance on the use of rapid antigen detection tests for identifying SARS-CoV-2 infection.
  2. Refer to package insert for full performance and best product experience.
  3. PCR is the gold standard for diagnosing COVID-19.